Precisemab Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 3

Precisemab General Information

Description

Developer of antibody technology intended for the safety of antibody drugs via our universal antibody lock technology. The company offers universal antibody lock mechanisms, enhanced selectivity features, and optimized structural configurations applicable to monoclonal antibodies, anti-drug antibodies, and bispecific antibodies, enabling healthcare professionals to give patients the safest possible therapy.

Contact Information

Formerly Known As
Tianshuo Biotech Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 17th Floor, No. 3, Yuanqu Street
  • Nangang District
  • Taipei City
  • Taiwan
+886 07
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 17th Floor, No. 3, Yuanqu Street
  • Nangang District
  • Taipei City
  • Taiwan
+886 07

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Precisemab Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 28-Feb-2024 Completed Generating Revenue
3. Early Stage VC 29-Jul-2022 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2021 Completed Generating Revenue
1. Grant 30-Nov-2019 $2M Completed Generating Revenue
To view Precisemab’s complete valuation and funding history, request access »

Precisemab Patents

Precisemab Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026184705-A1 Conditionally activated lock-anti-egfr antibody for cancer therapy Pending 07-Mar-2025

Precisemab Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Precisemab Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Paragon Investment Venture Capital Minority
Taiwan Phoenix Accelerator/Incubator Minority
Stpi Corporation Minority
To view Precisemab’s complete investors history, request access »

Precisemab FAQs

  • When was Precisemab founded?

    Precisemab was founded in 2011.

  • Where is Precisemab headquartered?

    Precisemab is headquartered in Taipei City, Taiwan.

  • What is the size of Precisemab?

    Precisemab has 5 total employees.

  • What industry is Precisemab in?

    Precisemab’s primary industry is Drug Discovery.

  • Is Precisemab a private or public company?

    Precisemab is a Private company.

  • What is Precisemab’s current revenue?

    The current revenue for Precisemab is .

  • How much funding has Precisemab raised over time?

    Precisemab has raised $1.6M.

  • Who are Precisemab’s investors?

    Paragon Investment, Taiwan Phoenix, and Stpi have invested in Precisemab.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process